Advertisement
UK markets close in 1 hour 45 minutes

  • FTSE 100

    8,075.24
    +30.43 (+0.38%)
     

  • FTSE 250

    19,771.47
    -28.25 (-0.14%)
     

  • AIM

    755.44
    +0.57 (+0.08%)
     

  • GBP/EUR

    1.1638
    +0.0011 (+0.09%)
     

  • GBP/USD

    1.2449
    -0.0004 (-0.03%)
     

  • Bitcoin GBP

    53,145.15
    -214.32 (-0.40%)
     

  • CMC Crypto 200

    1,427.71
    +3.61 (+0.25%)
     

  • S&P 500

    5,086.34
    +15.79 (+0.31%)
     

  • DOW

    38,466.53
    -37.16 (-0.10%)
     

  • CRUDE OIL

    82.83
    -0.53 (-0.64%)
     

  • GOLD FUTURES

    2,337.30
    -4.80 (-0.20%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     

  • DAX

    18,141.44
    +3.79 (+0.02%)
     

  • CAC 40

    8,128.20
    +22.42 (+0.28%)
     
Money:

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

Medical manufacturer settles charges it illegally kept high market share

Reuters - UK Focus

WASHINGTON, April 27 (Reuters) - Invibio, a division of Victrex PLC (LSE: VCT.L - news) that makes a key polymer used in spinal and other medical implants, agreed to settle allegations that it demanded exclusive contracts to illegally maintain its high market share, the Federal Trade Commission said on Wednesday.

The FTC said Invibio, which makes polyetheretherketone, or PEEK, insisted on long-term, exclusive or nearly exclusive contracts to maintain its 90 percent market share. This prevented competitors from effectively entering the market, the FTC said in a statement.

Under the settlement, Invibio will be barred from demanding exclusive contracts and must allow some customers to modify their contracts.

A spokesman for Invibio was not immediately available for comment. (Reporting by Diane Bartz; Editing by Bill Trott)